Compare FLL & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | LONA |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.2M | 90.4M |
| IPO Year | 2014 | N/A |
| Metric | FLL | LONA |
|---|---|---|
| Price | $2.98 | $8.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 254.4K | 27.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $302,376,000.00 | N/A |
| Revenue This Year | $7.54 | N/A |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $2.02 | $4.21 |
| 52 Week High | $4.95 | $14.21 |
| Indicator | FLL | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 37.91 |
| Support Level | $2.24 | $8.12 |
| Resistance Level | $2.98 | $11.44 |
| Average True Range (ATR) | 0.21 | 0.57 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 58.16 | 6.35 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.